Αποτελέσματα Αναζήτησης
3 Οκτ 2011 · The phase III, randomized, placebo-controlled Sequential Tarceva in Unresectable NSCLC (SATURN; BO18192) study evaluated maintenance erlotinib in patients with nonprogressive disease following first-line platinum-doublet chemotherapy.
The Sequential Tarceva in Unresectable NSCLC (SATURN) study investigated the use of maintenance erlotinib following the completion of first-line chemotherapy.
15 Οκτ 2010 · In the phase III SequentiAl Tarceva® in UnResectable NSCLC (SATURN; BO18192) study, maintenance therapy with erlotinib significantly increased progression-free and overall survival (PFS and OS) versus placebo in both the overall intention-to-treat (ITT) population and in patients with EGFR immunohistochemistry (IHC)-positive tumours . These ...
2 Αυγ 2009 · August 1, 2009 (San Francisco, California) — New results from the phase 3 SATURN trial show that erlotinib (Tarceva) maintenance therapy significantly improves overall survival in...
The Sequential Tarceva in Unresectable NSCLC (SATURN) trial was designed to investigate the effectiveness of maintenance erlotinib treatment until the time of progression, with the goal of prolonging overall survival and delaying disease progression .
29 Σεπ 2024 · Looking to pair up with a virtual study buddy for mutual motivation? We’ve gathered the best online study room websites and apps to study with strangers!
The Tarceva Lung Cancer Survival Treatment (TRUST) study was a large international, open-label, phase IV study of erlotinib, designed to allow access to erlotinib monotherapy for patients with advanced stage IIIB/IV NSCLC who had previously failed on or were considered unsuitable to receive standard chemotherapy or radiotherapy and were ...
